Product details
Background：Davutamig (REGN-5093) is a human immunoglobulin G4-kappa, anti-MET monoclonal antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic.
• MET-dependent solid tumours – molecular diagnosis and targeted therapy., PMID:32514147
• ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence., PMID:27573171
• Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis., PMID:34848680
• The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance., PMID:30786811
• The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions., PMID:26822708
• MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas., PMID:34667077
• Targeting HGF/c-MET Axis in Pancreatic Cancer., PMID:33271944
• Targeting the hepatocyte growth factor/Met pathway in cancer., PMID:28673936
• Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases., PMID:30658428
• Hepatocyte growth factor in physiology and infectious diseases., PMID:28094206
